eShowcase: CTSD Version 2.5

CTSD Version 2.5 provides improved data visualization and enhanced user interface

Phase Forward (Waltham, MA) has released Version 2.5 of its Clinical Trials Signal Detection (CTSD) system. CTSD detects, evaluates, and tracks potential safety signals, which allows biopharmaceutical companies to analyze and classify potential safety signals, develop a product safety profile, and make more informed decisions earlier in the drug development process.

CTSD 2.5 adds an enhanced user interface that features summary displays, data visualization tools, and access to trial data without programming. The user interface's interactive displays facilitate safety review workflow by including patient level drill downs, Lab Trend graphs, an Exposure Summary graph, and Kaplan-Meier plots. It also offers Hy's Law alerts and a full set of Standardized MedDRA Queries (SMQs).

The product is integrated with Phase Forward's Web Submission Data Manager (WebSDM) platform and offers CDISC support.

Phase Forward, (781) 890-7878, www.phaseforward.com